ATI 9242

Drug Profile

ATI 9242

Alternative Names: ATI-9242

Latest Information Update: 13 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARYx Therapeutics
  • Developer ARYx Therapeutics; Braeburn Pharmaceuticals
  • Class Antipsychotics
  • Mechanism of Action Acetylcholine stimulants; Dopamine release stimulants; GABA modulators; NMDA receptor modulators; Serotonin-7 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Schizophrenia

Most Recent Events

  • 09 Mar 2018 Cascadian Therapeutics has been acquired by Seattle Genetics
  • 08 Nov 2016 Braeburn Pharmaceuticals completes a phase I trial in Schizophrenia (In volunteers) in USA (NCT02824666)
  • 11 Jul 2016 No development reported - Phase-I for Schizophrenia (In volunteers) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top